Clinical Trials Logo

Clinical Trial Summary

Leber's hereditary optic neuropathy (LHON) is a rare mitochondrial genetic disorder characterized by optic nerve atrophy due to the degeneration of retinal ganglion cells, which leads to acute visual loss. Males are more likely to develop optic neuropathy than women. They experience blurring or clouding of vision in one eye. The fellow eye develops similar symptoms sequentially with a delay of weeks. This sudden vision loss has devastating consequences on the life course of young men, with the impact of LHON on their quality of life and loss of independence. Yet, data describing the impacts of LHON on the life-course of patients is lacking, with very little data available in the literature. This study aims to understand the life of patients living with LHON disease through the analysis of the impact of LHON on the quality of life and loss of independence of patients living in France and to accurately describe the consequences of the disease on their social, familial and professional life.


Clinical Trial Description

The protocol presents a retrospective study. Patients living in France with LOHN shall be informed about it and offered to enroll through patients' associations or experts involved. As part of the consent process, participants should be informed of the nature of the study and the objectives and that the replies would remain confidential and anonymous. After a brief screening, the study divides into two parts: one aiming at collecting quantitative data through 3 standard quality of life questionnaires, and one survey specially written for this study (sample of 25 patients, duration 2 hours). The second is a qualitative interview to deep dive into their personal, social, familial, and professional life (10 patients, duration is 50 minutes). The study contains the detailed sections: - Screening - A survey specially designed for the study - Quality of life through EQ-5D-5L - Quality of life through NEI VFQ- 25, specific for patients suffering from glaucoma - Quality of life through ARAMAV questionnaire specific for visually impaired people - An in-depth qualitative interview, specially designed to fit the requirements of the study ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05555784
Study type Observational
Source Argo Sante
Contact
Status Completed
Phase
Start date August 4, 2022
Completion date February 2, 2023

See also
  Status Clinical Trial Phase
Completed NCT02771379 - Post Authorisation Safety Study With Raxone in LHON Patients
Completed NCT02796274 - Historical Case Record Survey of Visual Acuity Data From Patients With Leber's Hereditary Optic Neuropathy (LHON)
Completed NCT02774005 - Study to Assess the Efficacy and Safety of Raxone in LHON Patients Phase 4
Recruiting NCT04912843 - Gene Therapy Clinical Trial for the Treatment Of Leber's HereDitary Optic Neuropathy Phase 2/Phase 3
Terminated NCT01389817 - Near-infrared Light-emitting Diode (NIR-LED) Therapy for Leber's Hereditary Optic Neuropathy (LHON) Phase 1/Phase 2